{"id":{"repo_id":"wfu","oai_identifier":"oai:wakespace.lib.wfu.edu:10339/57136"},"canonical_url":"https://search.dev.ndltd.org/etd/wfu/oai:wakespace.lib.wfu.edu:10339/57136","repository":{"repo_id":"wfu","name":"Wake Forest University","base_url":"https://wakespace.lib.wfu.edu/oai/request"},"display":{"title":"Studies of the efficacy of Ribonucleotide Reductase inhibition in preclinical models of Acute Myeloid Leukemia in combination with standard and novel therapeutics","abstract":"Acute Myeloid Leukemia (AML) is an aggressive disease of the marrow with approximately 18,800 new cases each year. The elderly population represents the bulk of AML patients with a median age of onset of 70. More than 70% of AML patients are over the age of 60, and for this group the 5 year overall survival rate is under 10%. There are multiple reasons for this, including complex karyotypes in elderly patients, other comorbidities, and chemoresistance. This group of patients needs more effective chemotherapeutic options.","abstract_html":"Acute Myeloid Leukemia (AML) is an aggressive disease of the marrow with approximately 18,800 new cases each year. The elderly population represents the bulk of AML patients with a median age of onset of 70. More than 70% of AML patients are over the age of 60, and for this group the 5 year overall survival rate is under 10%. There are multiple reasons for this, including complex karyotypes in elderly patients, other comorbidities, and chemoresistance. This group of patients needs more effective chemotherapeutic options.","abstract_has_math":false,"creators":["Cook, Guerry"],"institution":"Wake Forest University","degree_name":null,"degree_level":null,"degree_discipline":null,"degree_department":null,"school":null,"contributors":[],"advisors":[],"committee_chairs":[],"committee_members":[],"year":2015,"date_issued":"2015","date_published":"2015","updated_at":"2026-07-27T22:01:52Z","subjects":["Acute Myeloid Leukemia"],"languages":["en"],"rights":[],"rights_urls":[],"identifier_entries":[]},"links":{"outbound_url":"http://hdl.handle.net/10339/57136","outbound_label":"Handle","outbound_source":"dc:identifier.uri"},"metadata_groups":[{"id":"people","label":"People","entries":[{"key":"dc:creator","label":"Author","values":["Cook, Guerry"]}]},{"id":"academic_context","label":"Academic Context","entries":[{"key":"dc:date.accessioned","label":"Dc Date Accessioned","values":["2015-06-23T08:35:49Z"]},{"key":"dc:date.available","label":"Dc Date Available","values":["2015-12-22T09:30:10Z"]},{"key":"dc:date.issued","label":"Date","values":["2015"]},{"key":"dc:publisher","label":"Institution","values":["Wake Forest University"]},{"key":"dc:type","label":"Dc Type","values":["Dissertation"]}]},{"id":"subjects_keywords","label":"Subjects and Keywords","entries":[{"key":"dc:subject","label":"Dc Subject","values":["Acute Myeloid Leukemia"]}]},{"id":"language_rights","label":"Language and Rights","entries":[{"key":"dc:language.iso","label":"Language (ISO)","values":["en"]}]},{"id":"identifiers","label":"Identifiers","entries":[{"key":"dc:identifier.uri","label":"Identifier URI","values":["http://hdl.handle.net/10339/57136"]}]},{"id":"additional","label":"Additional Metadata","entries":[{"key":"dc:description.abstract","label":"Abstract","values":["Acute Myeloid Leukemia (AML) is an aggressive disease of the marrow with approximately 18,800 new cases each year. The elderly population represents the bulk of AML patients with a median age of onset of 70. More than 70% of AML patients are over the age of 60, and for this group the 5 year overall survival rate is under 10%. There are multiple reasons for this, including complex karyotypes in elderly patients, other comorbidities, and chemoresistance. This group of patients needs more effective chemotherapeutic options."]},{"key":"dc:title","label":"Title","values":["Studies of the efficacy of Ribonucleotide Reductase inhibition in preclinical models of Acute Myeloid Leukemia in combination with standard and novel therapeutics"]}]}],"canonical_facts":{"dc:creator":["Cook, Guerry"],"dc:date.accessioned":["2015-06-23T08:35:49Z"],"dc:date.available":["2015-12-22T09:30:10Z"],"dc:date.issued":["2015"],"dc:description.abstract":["Acute Myeloid Leukemia (AML) is an aggressive disease of the marrow with approximately 18,800 new cases each year. The elderly population represents the bulk of AML patients with a median age of onset of 70. More than 70% of AML patients are over the age of 60, and for this group the 5 year overall survival rate is under 10%. There are multiple reasons for this, including complex karyotypes in elderly patients, other comorbidities, and chemoresistance. This group of patients needs more effective chemotherapeutic options."],"dc:identifier.uri":["http://hdl.handle.net/10339/57136"],"dc:language.iso":["en"],"dc:publisher":["Wake Forest University"],"dc:subject":["Acute Myeloid Leukemia"],"dc:title":["Studies of the efficacy of Ribonucleotide Reductase inhibition in preclinical models of Acute Myeloid Leukemia in combination with standard and novel therapeutics"],"dc:type":["Dissertation"]},"updated_at":"2026-07-27T22:01:52Z"}